|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Treatment characteristics** | **All patients****N = 62 (100)** | **Abdominal wall DF****N = 46 (100)** | **Non-abdominal wall DF****N = 16 (100)** | *p-value* | **Diagnosis during pregnancy****N = 10 (100)** | **Diagnosis after pregnancy****N = 52 (100)** | *p-value* |
| **First line treatment** Active surveillance Surgery Systemic treatment b | 38 (61.3)23 (37.1)1 (1.6) | 30 (65.2)16 (34.8)0 (0.0) | 8 (50.0)7 (43.8)1 (6.3) | *.247a* | 5 (50.0)5 (50.0)0 (0.0) | 33 (63.5)18 (34.6)1 (1.9) | *.567a* |
| **Surgery as part of treatment (1st/2nd line)** Yes No | 30 (48.4)32 (51.6) | 22 (47.8)24 (52.2) | 8 (50.0)8 (50.0) | *1.00* | 5 (50.0)5 (50.0) | 25 (48.1)27 (51.9) | *1.00a* |
| **Medical therapy as part of treatment (1st/2nd/3rd line)**Yes No | 9 (14.5)53 (85.5) | 4 (8.7)42 (91.3) | 5 (31.2)11 (68.8) | ***.038a*** | 9 (90.0)1 (10.0) | 44 (84.6)8 (15.4) | *1.00a* |
| **Patient treated with surgery** | **N = 30 (100)** | **N = 22 (100)** | **N = 8 (100)** |  | **N = 5 (100)** | **N = 25 (100)** | *p-value* |
| **Resection margins** R0 R1 R2 Missing | 14 (48.3)14 (48.3)1 (3.4)1 | 10 (47.6)10 (47.6)1 (4.8)1 | 4 (50.0)4 (50.0)0 (0.0)0 | *1.00a* | 1 (20.0)4 (80.0)0 (0.0)0 | 13 (54.2)10 (41.7)1 (4.2)1 | *.447a* |
| **Surgical complications** None Incisional hernia Consistent pain in area of surgery | 26 (86.7)3 (10.0)1 (3.3) | 19 (86.4)2 (9.1)1 (4.5) | 7 (87.5)1 (12.5)0 (0.0) | *1.00a* | 5 (100)0 (0.0)0 (0.0) | 21 (84.0)3 (12.0)1 (4.0) | *1.00a* |
| **Surgery in sarcoma expertise center** Yes No | 20 (66.7)10 (33.3) | 14 (63.6)8 (36.4) | 2 (25.0)6 (75.0) | *.682a* | 3 (60.0)2 (40.0) | 17 (68.0)8 (32.0) | *1.00a* |

Table 2 – Treatment characteristics

**a)** Fisher’s exact. b) Celecoxib